NASDAQ:KPTI Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis $3.86 0.00 (0.00%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$3.95 +0.09 (+2.33%) As of 04/4/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Karyopharm Therapeutics Stock (NASDAQ:KPTI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get KPTI alerts:Sign Up Key Stats Today's Range$3.51▼$3.8950-Day Range$3.54▼$10.2952-Week Range$3.51▼$21.30Volume143,600 shsAverage Volume80,747 shsMarket Capitalization$32.49 millionP/E RatioN/ADividend YieldN/APrice Target$57.50Consensus RatingBuy Company OverviewKaryopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.Read More… Remove Ads Karyopharm Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreKPTI MarketRank™: Karyopharm Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 311th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingKaryopharm Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKaryopharm Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Karyopharm Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($0.71) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karyopharm Therapeutics is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karyopharm Therapeutics is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Karyopharm Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.63% of the float of Karyopharm Therapeutics has been sold short.Short Interest Ratio / Days to CoverKaryopharm Therapeutics has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.Change versus previous monthShort interest in Karyopharm Therapeutics has recently increased by 0.94%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKaryopharm Therapeutics does not currently pay a dividend.Dividend GrowthKaryopharm Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-1.11 Percentage of Shares Shorted13.63% of the float of Karyopharm Therapeutics has been sold short.Short Interest Ratio / Days to CoverKaryopharm Therapeutics has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.Change versus previous monthShort interest in Karyopharm Therapeutics has recently increased by 0.94%, indicating that investor sentiment is decreasing. News and Social Media1.3 / 5News Sentiment0.34 News SentimentKaryopharm Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Karyopharm Therapeutics this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 2 people have added Karyopharm Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -78% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Karyopharm Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.75% of the stock of Karyopharm Therapeutics is held by insiders.Percentage Held by Institutions66.44% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Karyopharm Therapeutics' insider trading history. Receive KPTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KPTI Stock News HeadlinesKaryopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200 Day Moving Average - Here's WhyApril 2 at 2:57 AM | americanbankingnews.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2025 | prnewswire.comNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. April 5, 2025 | Porter & Company (Ad)Karyopharm price target lowered to split-adjusted $15 from $75 at Piper SandlerMarch 20, 2025 | markets.businessinsider.comKaryopharm Therapeutics (KPTI) Receives a Buy from Piper SandlerMarch 20, 2025 | markets.businessinsider.comXPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APACMarch 5, 2025 | prnewswire.comKaryopharm price target lowered to $54 from $75 at BairdMarch 3, 2025 | markets.businessinsider.comKaryopharm Therapeutics Inc.'s SWOT analysis: biotech firm's stock faces pivotal yearFebruary 28, 2025 | uk.investing.comSee More Headlines KPTI Stock Analysis - Frequently Asked Questions How have KPTI shares performed this year? Karyopharm Therapeutics' stock was trading at $10.1445 on January 1st, 2025. Since then, KPTI stock has decreased by 61.9% and is now trading at $3.86. View the best growth stocks for 2025 here. How were Karyopharm Therapeutics' earnings last quarter? Karyopharm Therapeutics Inc. (NASDAQ:KPTI) released its quarterly earnings results on Wednesday, February, 19th. The company reported ($3.60) earnings per share for the quarter, beating analysts' consensus estimates of ($3.90) by $0.30. The firm earned $30.54 million during the quarter, compared to analyst estimates of $30.29 million. When did Karyopharm Therapeutics' stock split? Karyopharm Therapeutics shares reverse split before market open on Wednesday, February 26th 2025. The 1-15 reverse split was announced on Monday, February 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Karyopharm Therapeutics? Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Karyopharm Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Karyopharm Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Enovix (ENVX), Tesla (TSLA), Globant (GLOB), Luminar Technologies (LAZR) and Rambus (RMBS). Company Calendar Last Earnings2/19/2025Today4/05/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KPTI CIK1503802 Webwww.karyopharm.com Phone(617) 658-0600FaxN/AEmployees380Year FoundedN/APrice Target and Rating Average Stock Price Target$57.50 High Stock Price Target$75.00 Low Stock Price Target$45.00 Potential Upside/Downside+1,389.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($15.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-143,100,000.00 Net Margins-52.62% Pretax Margin-52.58% Return on EquityN/A Return on Assets-39.58% Debt Debt-to-Equity RatioN/A Current Ratio1.70 Quick Ratio2.93 Sales & Book Value Annual Sales$145.24 million Price / Sales0.22 Cash FlowN/A Price / Cash FlowN/A Book Value($1.47) per share Price / Book-2.63Miscellaneous Outstanding Shares8,417,000Free Float122,721,000Market Cap$32.49 million OptionableOptionable Beta0.11 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:KPTI) was last updated on 4/5/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.